ReviewInfectious diseases and therapy2020
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms.
Review in Infectious diseases and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 1 synthesis or guideline pooled it, 175 citations in OpenAlex.
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Pharmacokinetics, safety, and tolerability of HRS-8427, a novel anti-carbapenem-resistant cephalosporin, in healthy subjects.Antimicrobial agents and chemotherapy · 2026Trial
- Efficay of cefiderocol as salvage therapy in tricuspid endocarditis due to multidrug-resistantRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Article
- The Evolving Clonal, Plasmid-Mediated Resistome, Virulome and Therapeutic Landscape of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- The Role of Pyrrolidine in Antibacterial Drug Discovery: Clinically Approved Antibiotics, Novel Derivatives, and Future Perspectives.International journal of molecular sciences · 2026Review
- Bidentate Metal-Binding Motifs in US FDA Approved Small Molecule Drugs.Journal of medicinal chemistry · 2026Review
- Emerging Cross-Resistance to Cefiderocol and Ceftazidime-Avibactam in KPC-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Genomic and functional approaches point to potential determinants of neonatalMicrobiology spectrum · 2026Article
- Special Issue "Novel Mechanisms of Bacterial Antibiotic Resistance and Strategies to Fight Them".International journal of molecular sciences · 2026Article
- Synergistic Potential of Repurposing non-β-lactam Compounds as Class A serine β-lactamases Inhibitor: Insights from MolecularDocking, Molecular Dynamics Simulations and Antimicrobial Potentiation.Scientific reports · 2026Article
- Cefiderocol Is Effective In Vitro Against Numerous Gram-Negative Species Isolated from Keratitis Patients.Antibiotics (Basel, Switzerland) · 2026Article
- Genetic basis of cefiderocol resistance inMicrobiology spectrum · 2026Article
- Internal Ion Pairs Control Transport Through TonB-Dependent Siderophore Receptors.International journal of molecular sciences · 2026Article
- Emergence of a novel NDM-4-producingIDCases · 2026Article
- The dual implications of iron homeostasis as a bacterial threat: its roles in virulence and antimicrobial resistance.Archives of microbiology · 2025Review
- Use of Cefiderocol for Carbapenem-Resistant Gram-Negative Infections in Hospital at Home: Multicentric Real-World Experience.Antibiotics (Basel, Switzerland) · 2025Article
- Review
- Cefiderocol: A Comprehensive Review of Chemistry, Mechanisms of Resistance, and Clinical Applications in the Era of Multidrug Resistance.Current microbiology · 2025Review
- β-Lactam/β-Lactamase Inhibitor Combinations in Sepsis-Associated Acute Kidney Injury and Renal Replacement Therapy.Antibiotics (Basel, Switzerland) · 2025Review
- Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms.The Journal of antimicrobial chemotherapy · 2025Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefiderocol, formerly S-649266, is a first in its class, an injectable siderophore cephalosporin that combines a catechol-type siderophore and cephalosporin core with side chains similar to cefepime and ceftazidime. This structure and its unique mechanism of action confer enhanced stability against hydrolysis by many β-lactamases, including extended spectrum β-lactamases such as CTX-M, and carbapenemases such as KPC, NDM, VIM, IMP, OXA-23, OXA-48-like, OXA-51-like and OXA-58. Cefiderocol's spectrum of activity encompasses both lactose-fermenting and non-fermenting Gram-negative pathogens, including carbapenem-resistant Enterobacterales. Cefiderocol recently received US Food and Drug Administration approval for the treatment of complicated urinary tract infections, including pyelonephritis, and is currently being evaluated in phase III trials for nosocomial pneumonia and infections caused by carbapenem-resistant Gram-negative pathogens. The purpose of this article is to review existing data on the mechanism of action, microbiology, pharmacokinetics, pharmacodynamics, efficacy, and safety of cefiderocol to assist clinicians in determining its place in therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.